ArticleTranslational cancer research2026
The prognostic predictive value of monocyte to high-density lipoprotein cholesterol ratio in HR+/HER- breast cancer patients.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Though hormone receptors (HRs) [estrogen receptor (ER) and progesterone receptor (PR)] positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer patients generally have a good prognosis, recurrence rate of HR+/HER2- breast cancer extends over 20 years from diagnosis. Monocyte to high-density lipoprotein cholesterol ratio (MHR) emerges as a novel biomarker for risk stratification in breast cancer. The purpose of the study was to develop and validate a nomogram for predicting the prognosis of HR+/HER- breast cancer. Methods: A total of 310 patients with HR+/HER- breast cancer were recruited and randomly divided into two groups. The study's endpoints comprised disease-free survival (DFS) and overall survival (OS). The concordance index (C-index), area under the curve (AUC), and calibration curves served as the primary indicators for evaluating the nomogram's predictive accuracy and discriminative ability. Results: Age, tumor size, lymph node metastasis (LNM), neutrophil to lymphocyte ratio and MHR were used to construct the nomogram for DFS. The nomogram demonstrated robust discrimination, yielding C-index values of 0.781 in the training group and 0.733 in the validation group. Calibration curves showed good agreement. Conclusions: We developed and validated a well-calibrated nomogram for predicting DFS in patients with HR+/HER- breast cancer. This nomogram uniquely integrates MHR with clinicopathological factors to predict prognosis in HR+/HER2- breast cancer and can facilitate individualized therapeutic planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.